Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-1205
- Development stage
- Unknown
- Lead developer
- Atterx BioTherapeutics
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intraurethral
01
Overview
C-1205 is a live biotherapeutic product (LBP) developed by Atterx BioTherapeutics for the prevention of catheter-associated urinary tract infections (CAUTIs). It is formulated as a lyophilized powder containing a non-pathogenic strain of *Escherichia coli* (HU2117) and a gelling agent. When reconstituted with water, it forms a thick gel used to coat urinary catheters during insertion, replacing standard lubricants. The drug works through bacterial interference, where the harmless *E. coli* strain colonizes the bladder and catheter surface to prevent the establishment of pathogenic bacteria and fungi. C-1205 has received Fast Track Designation from the FDA and is entering Phase 1/2 clinical development.
- Other names
- HU2117HU-2117HU 2117Escherichia coli HU2117
Beyond the preview
Go deeper on C-1205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-1205.